Parallel Comparison of 18 Gene Classifiers and Oncotype DX (Nanostring)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03772197|
Recruitment Status : Completed
First Posted : December 11, 2018
Last Update Posted : December 19, 2018
|Condition or disease|
|Breast Cancer Recurrence|
With improved diagnosis, breast cancer can now be detected at early stages, thus improving survival rates. However, overtreatment is common; considering that the risk of recurrence is low, patients may suffer from side effects without receiving the full benefits of adjuvant therapies.
To overcome the imprecision of prognosis based on clinicopathologic factors, genomic tests for breast cancer prognosis, such as the Oncotype DX® (ODx), MammaPrint®, and EndoPredict® assay kits, are frequently utilized. These multigene panels were development based on Caucasian populations, and may not suitable to Asian population due to the differences in the incidence and lifestyle of breast cancer patients from different ethic backgrounds. To fiil this gap, an 18-gene classifier (18-GC) based on the gene-expression profiling of Chinese breast cancer patients was developed
In the current study, investigators combined clinical variables and genetic information to generate a clinical-genomic model: RI-DR, a recurrence index for distant recurrence (based on a genomic model and 6 clinical variables: age, tumor size, lymph node status, estrogen receptor status, lymphovascular invasion, tumor grading).
By using tissues that have been tested with ODx, in this study, investigators evaluated the performance of the RI-DR model with that of the ODx assay in the prognosis assessment of a cohort of patients from Taiwan.
|Study Type :||Observational|
|Actual Enrollment :||138 participants|
|Official Title:||Head-to-Head Comparison of 18-Gene-Based Clinical-Genomic Model and Oncotype DX 21-Gene Assay for Predicting Recurrence of Early-stage Breast Cancer|
|Actual Study Start Date :||June 1, 2018|
|Actual Primary Completion Date :||October 18, 2018|
|Actual Study Completion Date :||November 1, 2018|
- The locoregional recurrence (LRR) rate, within 5 years after surgery. [ Time Frame: 5 years ]LRR risk calculated by 18-GC of breast cancer patients would be classified into high risk
- The distant recurrence(DR) rate, within 5 years after surgery. [ Time Frame: 5 years ]DR risk calculated by 18-GC of breast cancer patients would be classified into high risk
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03772197
|Taipei, Taiwan, 106|
|Principal Investigator:||Skye Cheng||AMWISE DIAGNOSTICS PTE. LDT.|